Literature DB >> 15681439

Influence of the human parainfluenza virus 3 attachment protein's neuraminidase activity on its capacity to activate the fusion protein.

Matteo Porotto1, Matthew Murrell, Olga Greengard, Lynne Doctor, Anne Moscona.   

Abstract

In order to examine functions of the hemagglutinin-neuraminidase (HN) protein that quantitatively influence fusion promotion, human parainfluenza virus 3 (HPIV3) variants with alterations in HN were studied. The variant HNs have mutations that affect either receptor binding avidity, neuraminidase activity, or fusion protein (F) activation. Neuraminidase activity was regulated by manipulation of temperature and pH. F activation was assessed by quantitating the irreversible binding of target erythrocytes (RBC) to HN/F-coexpressing cells in the presence of 4-GU-DANA (zanamivir) to release target cells bound only by HN-receptor interactions; the remaining, irreversibly bound target cells are retained via the fusion protein. In cells coexpressing wild-type (wt) or variant HNs with wt F, the fusion promotion capacity of HN was distinguished from target cell binding by measuring changes with time in the amounts of target RBC that were (i) reversibly bound by HN-receptor interaction (released only upon the addition of 4-GU-DANA), (ii) released by HN's neuraminidase, and (iii) irreversibly bound by F-insertion or fusion (F triggered). For wt HN, lowering the pH (to approach the optimum for HPIV3 neuraminidase) decreased F triggering via release of HN from its receptor. An HN variant with increased receptor binding avidity had F-triggering efficiency like that of wt HN at pH 8.0, but this efficiency was not decreased by lowering the pH to 5.7, which suggested that the variant HN's higher receptor binding activity counterbalanced the receptor dissociation promoted by increased neuraminidase activity. To dissect the specific contribution of neuraminidase to triggering, two variant HNs that are triggering-defective due to a mutation in the HN stalk were evaluated. One of these variants has, in addition, a mutation in the globular head that renders it neuraminidase dead, while the HN with the stalk mutation alone has 30% of wt neuraminidase. While the variant without neuraminidase activity triggered F effectively at 37 degrees C irrespective of pH, the variant possessing effective neuraminidase activity completely failed to activate F at pH 5.7 and was capable of only minimal triggering activity even at pH 8.0. These results demonstrate that neuraminidase activity impacts the extent of HPIV3-mediated fusion by releasing HN from contact with receptor. Any particular HN's competence to promote F-mediated fusion depends on the balance between its inherent F-triggering efficacy and its receptor-attachment regulatory functions (binding and receptor cleavage).

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15681439      PMCID: PMC546598          DOI: 10.1128/JVI.79.4.2383-2392.2005

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  46 in total

1.  The release of influenza virus from the infected cell.

Authors:  L HOYLE
Journal:  J Hyg (Lond)       Date:  1954-06

2.  Mutations in the Newcastle disease virus hemagglutinin-neuraminidase protein that interfere with its ability to interact with the homologous F protein in the promotion of fusion.

Authors:  R Deng; Z Wang; P J Mahon; M Marinello; A Mirza; R M Iorio
Journal:  Virology       Date:  1999-01-05       Impact factor: 3.616

3.  Virus-receptor interactions of human parainfluenza viruses types 1, 2 and 3.

Authors:  C Ah-Tye; S Schwartz; K Huberman; E Carlin; A Moscona
Journal:  Microb Pathog       Date:  1999-11       Impact factor: 3.738

4.  Mutational analysis of heptad repeats in the membrane-proximal region of Newcastle disease virus HN protein.

Authors:  J Stone-Hulslander; T G Morrison
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

5.  Functional interaction of paramyxovirus glycoproteins: identification of a domain in Sendai virus HN which promotes cell fusion.

Authors:  K Tanabayashi; R W Compans
Journal:  J Virol       Date:  1996-09       Impact factor: 5.103

6.  Acidic pH enhancement of the fusion of Newcastle disease virus with cultured cells.

Authors:  K San Román; E Villar; I Muñoz-Barroso
Journal:  Virology       Date:  1999-08-01       Impact factor: 3.616

7.  The use of a quantitative fusion assay to evaluate HN-receptor interaction for human parainfluenza virus type 3.

Authors:  S Levin Perlman; M Jordan; R Brossmer; O Greengard; A Moscona
Journal:  Virology       Date:  1999-12-05       Impact factor: 3.616

8.  Hemagglutinin specificity and neuraminidase coding capacity of neuraminidase-deficient influenza viruses.

Authors:  P Yang; A Bansal; C Liu; G M Air
Journal:  Virology       Date:  1997-03-03       Impact factor: 3.616

9.  Hemagglutinin-neuraminidase of human parainfluenza 3: role of the neuraminidase in the viral life cycle.

Authors:  K Huberman; R W Peluso; A Moscona
Journal:  Virology       Date:  1995-12-01       Impact factor: 3.616

10.  Transfer of an esterase-resistant receptor analog to the surface of influenza C virions results in reduced infectivity due to aggregate formation.

Authors:  K Höfling; R Brossmer; H Klenk; G Herrler
Journal:  Virology       Date:  1996-04-01       Impact factor: 3.616

View more
  39 in total

1.  Identification of domains on the fusion (F) protein trimer that influence the hemagglutinin-neuraminidase specificity of the f protein in mediating cell-cell fusion.

Authors:  Masato Tsurudome; Morihiro Ito; Machiko Nishio; Mito Nakahashi; Mitsuo Kawano; Hiroshi Komada; Tetsuya Nosaka; Yasuhiko Ito
Journal:  J Virol       Date:  2011-01-26       Impact factor: 5.103

2.  Inhibition of hendra virus fusion.

Authors:  M Porotto; L Doctor; P Carta; M Fornabaio; O Greengard; G E Kellogg; A Moscona
Journal:  J Virol       Date:  2006-10       Impact factor: 5.103

3.  Mutation at residue 523 creates a second receptor binding site on human parainfluenza virus type 1 hemagglutinin-neuraminidase protein.

Authors:  Tatiana Bousse; Toru Takimoto
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

4.  Paramyxovirus receptor-binding molecules: engagement of one site on the hemagglutinin-neuraminidase protein modulates activity at the second site.

Authors:  Matteo Porotto; Micaela Fornabaio; Olga Greengard; Matthew T Murrell; Glen E Kellogg; Anne Moscona
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

5.  Spring-loaded heptad repeat residues regulate the expression and activation of paramyxovirus fusion protein.

Authors:  Laura E Luque; Charles J Russell
Journal:  J Virol       Date:  2007-01-24       Impact factor: 5.103

6.  A second receptor binding site on human parainfluenza virus type 3 hemagglutinin-neuraminidase contributes to activation of the fusion mechanism.

Authors:  Matteo Porotto; Micaela Fornabaio; Glen E Kellogg; Anne Moscona
Journal:  J Virol       Date:  2007-01-17       Impact factor: 5.103

7.  Addition of N-glycans in the stalk of the Newcastle disease virus HN protein blocks its interaction with the F protein and prevents fusion.

Authors:  Vanessa R Melanson; Ronald M Iorio
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

8.  Kinetic dependence of paramyxovirus entry inhibition.

Authors:  Matteo Porotto; Christine C Yokoyama; Gianmarco Orefice; Han-Sung Kim; Mohamed Aljofan; Bruce A Mungall; Anne Moscona
Journal:  J Virol       Date:  2009-04-15       Impact factor: 5.103

9.  Effects of hemagglutinin-neuraminidase protein mutations on cell-cell fusion mediated by human parainfluenza type 2 virus.

Authors:  Masato Tsurudome; Machiko Nishio; Morihiro Ito; Shunsuke Tanahashi; Mitsuo Kawano; Hiroshi Komada; Yasuhiko Ito
Journal:  J Virol       Date:  2008-06-18       Impact factor: 5.103

10.  N-linked glycan at residue 523 of human parainfluenza virus type 3 hemagglutinin-neuraminidase masks a second receptor-binding site.

Authors:  Vasiliy P Mishin; Makiko Watanabe; Garry Taylor; John Devincenzo; Michael Bose; Allen Portner; Irina V Alymova
Journal:  J Virol       Date:  2010-01-06       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.